TYRA-200
TYRA-200 is an orally active FGFR1/2/3 inhibitor. TYRA-200 shows dose-dependent tumor regression in both wild-type FGFR2 and FGFR2 mutant mice model. TYRA-200 can be used for advanced or metastatic intrahepatic cholangiocarcinoma and other FGFR2-driven solid tumors research[1].
Product Specifications
CAS Number
2823289-77-4
UNSPSC
12352005
Target
FGFR
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Concentration
10mM
Purity
98.0500
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C=CC(NC1=CC2=C(N(C=C2C)C3=C(C=NC(NC4=CN(N=C4)CC(C)(O)C)=N3)F)C=C1)=O
Molecular Formula
C23H24FN7O2
Molecular Weight
449.48
References & Citations
[1]Rodon Ahnert J, et al. A multicenter, open-label, first-in-human study of TYRA-200 in advanced intrahepatic cholangiocarcinoma and other solid tumors with activating FGFR2 gene alterations (SURF201) [J]. 2025.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
FGF21; FGFR2; FGFR3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
